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Abstract
Background: The erythrocyte polymorphism, Southeast Asian ovalocytosis (SAO) (which results from a 27-base pair deletion
in the erythrocyte band 3 gene, SLC4A1D27) protects against cerebral malaria caused by Plasmodium falciparum; however, it
is unknown whether this polymorphism also protects against P. vivax infection and disease.
Methods and Findings: The association between SAO and P. vivax infection was examined through genotyping of 1,975
children enrolled in three independent epidemiological studies conducted in the Madang area of Papua New Guinea. SAO
was associated with a statistically significant 46% reduction in the incidence of clinical P. vivax episodes (adjusted incidence
rate ratio [IRR] = 0.54, 95% CI 0.40–0.72, p,0.0001) in a cohort of infants aged 3–21 months and a significant 52% reduction
in P. vivax (blood-stage) reinfection diagnosed by PCR (95% CI 22–71, p= 0.003) and 55% by light microscopy (95% CI 13–77,
p= 0.014), respectively, in a cohort of children aged 5–14 years. SAO was also associated with a reduction in risk of P. vivax
parasitaemia in children 3–21 months (1,111/ml versus 636/ml, p= 0.011) and prevalence of P. vivax infections in children 15–
21 months (odds ratio [OR] = 0.39, 95% CI 0.23–0.67, p= 0.001). In a case-control study of children aged 0.5–10 years, no
child with SAO was found among 27 cases with severe P. vivax or mixed P. falciparum/P. vivax malaria (OR= 0, 95% CI 0–1.56,
p= 0.11). SAO was associated with protection against severe P. falciparum malaria (OR= 0.38, 95% CI 0.15–0.87, p= 0.014)
but no effect was seen on either the risk of acquiring blood-stage infections or uncomplicated episodes with P. falciparum.
Although Duffy antigen receptor expression and function were not affected on SAO erythrocytes compared to non-SAO
children, high level (.90% binding inhibition) P. vivax Duffy binding protein–specific binding inhibitory antibodies were
observed significantly more often in sera from SAO than non-SAO children (SAO, 22.2%; non-SAO, 6.7%; p= 0.008).
Conclusions: In three independent studies, we observed strong associations between SAO and protection against P. vivax
malaria by a mechanism that is independent of the Duffy antigen. P. vivax malaria may have contributed to shaping the
unique host genetic adaptations to malaria in Asian and Oceanic populations.
Please see later in the article for the Editors’ Summary.
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Introduction
The populations of the southwest Pacific are highly diverse and
exhibit a range of unique red blood cell (RBC) polymorphisms.
Within Papua New Guinea (PNG), a variety of RBC variants are
found that have geographical patterns paralleling malaria ende-
micity [1], suggesting selective pressure by this disease [2]. In
particular, Southeast Asian ovalocytosis (SAO) (caused by band 3
deletion SLC4A1D27) has a distribution that is closely correlated
with malaria prevalence [3]. Even though the SLC4A1D27 deletion
is lethal in the homozygous state [4], prevalence of heterozygosity
reaches 35% in some PNG coastal populations [3]. Therefore, the
SLC4A1D27 deletion is thought to be associated with improved
survival against malaria in these populations. Indeed, SAO has
been associated with complete protection against cerebral but not
other forms of severe P. falciparum malaria in previous epidemi-
ological studies in PNG [5]. SAO was, however, found to have
little or no association with reduced prevalence, parasitaemia, or
uncomplicated falciparum malaria [6–8].
Although non-falciparum parasites are often considered to cause
only mild disease, recent data from the island of New Guinea [9–
11], Brazil [12], and India [13] show that P. vivax infections are
associated with severe disease and mortality. In addition, mortality
rates of 5% to 15% were regularly observed in patients challenged
with P. vivax for therapy of tertiary syphilis [14–18]. Thus, P. vivax
may be responsible for, or contribute to, natural selection of
erythrocyte polymorphisms. This selective pressure is suggested by
the emergence of the unique, non-African Duffy-negative allele
(FY*AES) in PNG and the observation that PNG children
expressing heterozygotes (FY*A/FY*AES) are protected from P.
vivax blood-stage infection [19]. The proposed Austronesian origin
of SLC4A1D27 [20], and its geographical restriction to Southeast
Asia and the southwest Pacific, regions that are co-endemic for all
four human malaria parasite species, led us to hypothesize that P.
vivax malaria could have contributed to selection of this genetic
polymorphism. An early cross-sectional [21] and a case-control
study [6] indicated that Melanesians with hereditary ovalocytosis
experienced lower parasitaemia and frequency of infection with P.
vivax and/or P. malariae. While three field studies have investigated
associations between SLC4A1D27 and prevalence of P. vivax blood-
stage infection, no significant relationship with susceptibility to
infection was observed [7,22,23]. However, these were small cross-
sectional studies with insufficient statistical power to unmask an
association.
In vitro studies have shown that SAO red cells are relatively
resistant to invasion by some P. falciparum isolates [24,25], with the
degree of resistance influenced by the ‘‘receptor preferences’’ of
the isolate [26] and deformability of the red cell membrane [25].
Ovalocytes exhibit reduced susceptibility to invasion by P. knowlesi
in vitro, with the suggestion that this is mediated by diminished
adherence [27]. These observations indicate that SAO may
protect against infection with P. vivax malaria in vivo.
In order to assess the relationship between SAO (i.e.,
SLC4A1D27) and risk of infection and/or disease with P. vivax,
we genotyped 1,975 children participating in three separate studies
conducted in the Madang area of PNG: (i) a cohort of infants
participating in a clinical trial of intermittent preventative
treatment (IPTi) [28], (ii) a pediatric severe malaria case-control
study [29], and (iii) a cohort of children aged 5–14 y that took part
in a prospective longitudinal cohort study in which all individuals
were initially treated to clear blood-stage infection and subse-
quently evaluated for a delay in time-to-reinfection by all
Plasmodium species [30].
Methods
Description of Field Studies
Infant cohort. Between July 2006 and June 2009, a total of
1,121 infants 3 mo of age were enrolled in a randomized, placebo-
control trial of intermittent preventive treatment for the preven-
tion of malaria and anemia [28]. After screening, consent, and
enrolment children were randomized to receive a full treatment
course of either amodiaquine+sulphadoxine/pyramethamine (SP),
artesunate+SP, or placebo at 3, 6, 9, and 12 mo. A total of 1,079
children completed follow-up until 15 mo of age, with an
additional 857 followed to 21 mo. At each treatment/follow-up
time point, bednet usage was assessed, recent antimalarial
treatment documented, and a 250-ml finger-prick blood sample
was collected from all children for later detection of infection (by
light microscopy [LM] and post-PCR ligase detection reaction-
fluorescent microsphere assay [LDR-FMA] [31]). A full clinical
examination was only conducted on children spontaneously
reporting signs of clinical illness. A passive case detection system
was maintained at the local health centre, three associated aid
posts, and a system of monthly study clinics for the entire study
period.
All children presenting with self-reported signs of a febrile illness
were promptly assessed for presence of malaria infection by rapid
diagnostic test (RDT) (ICT Combo test), and only RDT positive
children treated with arthemeter-lumefantrine (Coartem, Novar-
tis). A finger-prick sample was collected from all febrile cases for
confirmation of malarial infections by LM and PCR. For clinical
management and analysis purposes, malarial illness was defined as
axillary temperature .37.5uC, or history of fever in preceding
48 h, plus an infection of any density by LM and/or a positive
RDT with speciation subsequently confirmed by PCR. A more
detailed description of the study and its primary outcomes is given
elsewhere [28].
Pediatric severe malaria case-control study. Between
October 2006 and December 2009, a total of 318 children of
Madang or Sepik parentage aged 0.5–10 y admitted to the
pediatric ward of Modilon Hospital, Madang Town with a
diagnosis of severe malaria and 330 age-, location-, and ethnicity-
matched healthy controls were enrolled in a case-control study
designed to investigate the associations of host genetic polymor-
phism with protection against severe malaria. Cases were defined
as severe malaria if they fulfilled the World Health Organization
(WHO) definition of severe malarial illness [32]. Inclusion criteria
included any of: (i) impaired consciousness/coma (Blantyre Coma
Score [BCS],5 [23]); (ii) prostration (inability to sit/stand
unaided); (iii) multiple seizures; (iv) hyperlactatemia (blood lactate
.5 mmol/l); (v) severe anemia (hemoglobin ,50 g/l); (vi) dark
urine; (vii) hypoglycemia (blood glucose ,2.2 mmol/l); (viii)
jaundice; (ix) respiratory distress; (x) persistent vomiting; (xi)
abnormal bleeding; or (xii) signs of shock [29]. Where clinically
indicated, CSF (n=124) and blood (n=281 cultures were taken on
admission. All bacterial cultures from severe malaria cases were
sterile [29]. Healthy community controls were recruited from the
village of origin of the matched cases. At enrolment, a blood
sample for determination of malaria (by LM and nested PCR [33])
and for host genotyping was collected from each case and control.
A detailed description of all study procedures and in-depth clinical
description of all cases is given elsewhere [29]. As specified in the
study protocol, the primary case definition of a severe malaria case
for analysis of host genetic associations included the following
additional criteria: parasitaemia (.1,000 P. falciparum/ml or .500
P. vivax/ml) and parents from the PNG North Coast (Madang,
Morobe, and Sepik) (http://www.malariagen.net/node/242).
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Consequently, severe cases with mixed P. falciparum/P. vivax
infections by LM or PCR were only included as mixed cases if
both species exceeded their respective thresholds. The parasitae-
mia cut-offs were based on local attributable fraction-based
definitions of malaria episodes [34] and were included to increase
the specificity of case definition.
Treatment time-to-reinfection study. The study popula-
tion of 206 children for this treatment time-to-reinfection study has
been described previously [30]. Briefly, 206 elementary and
primary school students from Madang Province (Mugil and
Megiar) participated in this study conducted from June to
December, 2004. At enrolment, a peripheral venous blood sample
was collected for determination of Plasmodium species infection
status by LM and LDR-FMA. All children irrespective of infection
status were treated with a 7-d course of artesunate monotherapy
(4 mg/kg on day 1 and 2 mg/kg on days 2–7) that successfully
cleared all but one P. vivax infection [30]. As no primaquine was
given, subsequent P. vivax reinfections of the blood stream can
either be from newly acquired infection via sporozoites or
relapsing infections from hypnozoites.
Following treatment, children were followed up by active
surveillance every 2 wk and passive surveillance at the local health
centre for a total of 25 wk. Children were monitored for
acquisition of new infections until they completed follow-up,
withdrew from the study, or did not provide two consecutive bi-
weekly blood samples. At the time of the study, bednet usage in the
area was limited, most nets were untreated, and their use was not
associated with differences in risk of reinfection [30].
At each bi-weekly follow-up visit, a 250-ml finger-prick blood
sample was collected from each child for detection of malaria by
LM and LDR-FMA. If a child presented with clinical malaria
symptoms at a follow-up visit or during the intervening period, a
peripheral venous blood sample was taken and treatment given in
accordance with 2000 PNG guidelines (amodiaquine [3 d] plus
sulfadoxine/pyrimethamine on day 1).
These studies were reviewed and approved by institutional review
boards of PNG Medical Research Advisory Council, the IMR
Institutional Review Board, the Walter & Eliza Hall Institute, and
the Veterans Affairs Medical Center (Cleveland, Ohio, US).
Detection of Plasmodium Species Infection
Standard procedures were used for reading the blood smears
and estimating parasite densities [28–30]. All blood smears were
read independently by two experienced microscopists with
parasites counted against 200 white cells. Discrepant results were
adjudicated by a third microscopist. Blood smears were scored as
LM positive for an individual Plasmodium species if the species was
detected independently by at least two microscopists and/or
subsequent PCR-based analysis confirmed the presence of the
species. Densities were converted to the number of parasites per ml
of blood assuming 8,000 white blood cells/ml [35].
DNA was extracted using the QIAamp96 DNA Blood kit
(Qiagen) from all blood samples. Infection by each of the four
human malaria species co-endemic in PNG (P. falciparum, P. vivax,
P. malariae, and P. ovale) was assessed in all blood samples collected
in the two cohorts using a semi-quantitative post-PCR LDR-FMA
[31] and by nested PCR (nPCR) [36] in samples from the case-
control study. Both assays are based on the amplification of the
small subunit (SSU) ribosomal RNA gene.
PCR-Based Genotyping
Deletion and SNP genotyping of SLC4A1D27 (Chromosome 17)
associated with SAO, glycophorin C exon 3 deletion (GYPCDex3;
Chromosome 2) associated with Gerbich-negativity [37,38], the
common Melanesian 3.7 kb (a23.7) and 4.2 kb (a24.2) a-globin
(Chromosome 16) deletions associated with a+-thalassaemia [39],
and Duffy blood group polymorphisms were all performed using
methods that have been described previously [40].
Flow Cytometry-Based Analyses of Duffy Antigen on
RBCs
Twelve of 21 SAO children participating in the treatment time-
to-reinfection study agreed to provide an additional finger-prick
blood sample for flow cytometry-based analyses of Duffy antigen
on their red cells. For each SAO child, a control sample was
collected from a non-SAO (wild-type) child living in the same
hamlet. All samples collected were separated into plasma and cell
pellets. One sample from an SAO child was subsequently
discarded because of excessive cell lysis. Pelleted blood was
suspended in 1 ml of 10% DMSO+90% fetal calf serum solution
and frozen to 280uC. Prior to antibody staining and protein
binding, cells were rapidly thawed for 1 min in 37uC water bath
and washed (26) by first resuspending the red cell pellet in 1.0 ml
of RPMI-1640 followed by centrifugation at 600g for 10 min. In
order to assess Duffy receptor RBC surface expression for
individual blood donors, 16106 RBC from each sample were
incubated with 50 ml (1:50) of mouse anti-human Fy6 antibody for
15 min at 37uC. Cells were then washed with RPMI-1640, stained
with PE-conjugated goat anti-mouse antibody (Molecular Probes),
and analyzed using a Becton Dickinson LSR II (Franklin Lakes).
To assess possibility that there are differences in the ability of P.
vivax parasites to bind to SAO versus non-SAO RBC, we evaluated
the level of P. vivax Duffy binding protein (PvDBP) binding using
the same set of blood samples as described above [41]. Briefly,
16106 washed RBC from each sample were re-suspended in
200 ml of RPMI-1640 and exposed to 0.5 mg of recombinant
PvDBP region II (PvDBPII, Sal I variant) for 15 min at 37uC.
Excess protein was removed by centrifugation of erythrocytes at
3,000g for 2 min, resuspended in RPMI-1640 followed by
centrifugation at 3,000g for 2 min (26), and then resuspended in
100 ml of RPMI-1640 to which rabbit anti-PvDBPII antibody
(1:5,000 final dilution) was added and incubated for 30 min at
37uC, washed (26) as above and resuspended in 100 ml of RPMI-
1640 to which 1:4 to 1:16 dilution of PE-conjugated goat anti-
rabbit antibody (Sigma-Aldrich Co., depending on the lot of
conjugated antibody). All data were evaluated as normalized mean
fluorescence index (nMFI=% of positives cells6MFI) [42].
Measurement of Antibody Titers to Recombinant PvDBPII
Variants and Blocking Antibodies
Measurement of binding inhibitory antibodies (BIAbs) and total
antibodies to PvDBPII PvMSP1, PvRBP1, PvRBP2, and PvRBP3
was performed as previously described [43,44].
Statistical Analyses
The association of malaria incidence rates with SAO genotype
in children 3–21 mo was assessed using negative binomial
regression. Analyses were adjusted for gender, treatment effect,
season (wet versus dry), and village of enrolment (grouped by 12
recruitment zones). The time-at-risk was calculated starting on the
date of enrolment until the child either reached the final study
time point at 21 mo of age, or was withdrawn from the study [45].
Associations between SAO and the prevalence and density of P.
vivax and P. falciparum infections were investigated using general-
ized estimating equation models (XTLOGIT and XTREG in
STATA 10.0) that allowed accurate assessment of both variations
in the outcome and the correlations between repeated measure-
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ments in individual children (modeled using an exchangeable
correlation structure). A semi-robust Huber/White/sandwich
estimator of variance was used to assure valid standard errors.
Best fitting models were determined by backward elimination
using Wald’s Chi-square tests for individual variables.
In the study of children 5–14 y, log-rank tests were used to
assess differences in Kaplan-Meier curves of time-to-first reinfec-
tion as detected by LDR-FMA or LM. Cox regression was
employed to test for differences in time-to-first reinfection after
adjusting for all other factors that were found to be associated with
difference in time-to-first reinfection [30]. In these analyses
children were considered at risk of acquiring a Plasmodium spp.
infection until they either reached the end point, missed two
consecutive bi-weekly follow-ups, were re-treated with antimalar-
ials, or withdrew from the study.
Difference in frequency of SAO genotype among severe malaria
cases and controls were tested using x2 tests. Association of SAO
genotype with other common RBC polymorphisms and potential
confounders were assessed using x2 and Student t-tests (for
continuous, normally distributed variables). The associations
between different genetic traits and prevalence of BIAbs against
PvDBPII were assessed using Chi-square and Fisher exact tests.
Due to non-normality, differences in both expression of the Duffy
receptor on RBC and in binding of recombinant PvDBPII on
SAO and non-SAO RBCs were compared using non-parametric
Mann-Whitney U-tests.
All 95% confidence intervals are model based. Further details
on statistical approaches employed are given elsewhere [30,45].
All statistical analyses were performed using STATA 8 & 10 (Stata
Corporation) statistical analysis software.
Results
Association of SAO with Incidence of Clinical Malaria
A total of 1,121 children (48.3% female) were enrolled in the
IPTi trial, with equal numbers in each treatment arm. Of these,
857 were followed up to 21 mo. Over the entire 18-mo follow-up
period, children on average experienced 0.74 P. vivax and 0.28 P.
falciparum episodes/child/year. IPTi with amodiaquine-SP re-
duced the incidence of P. vivax by 23% (95% CI 0–41, p=0.048)
for the first year of follow-up (3–15 mo) and incidence of P.
falciparum by 35% (95% CI 9–54, p=0.012), whereas IPTi with
artesunate-SP only protected against P. falciparum (31%, 95% CI
4–51, p=0.027) but not against P. vivax episodes (6%, 95% CI
224 to 26, p=0.759) [28]. No significant differences were
observed between all three arms for the 15–21-mo extended
follow-up period (p.0.75).
SAO genotypes were available for all 1,121 children with 130
heterozygous for SLC4A1D27 (11.6%), with no significant differ-
ence in frequency of SAO among treatment arms (p=0.30).
SLC4A1D27 heterozygocity was associated with neither a+thalas-
saemia nor Gerbich-negative deletion (GPYCDex3, p.0.95) (Table
S1). There were no differences between SAO and wild-type
children in bednet usage or village of residence, gender, or season
of recruitment (p.0.36).
Over the total follow-up period (3–21 mo), SAO was associated
with a significant 32% reduction in incidence of any form of
malaria (95% CI 11–49, p=0.0068) (Table 1). The protection was
exclusively directed against episodes of P. vivax malaria, with the
SAO genotype associated with 43% reduction (95% CI 22–59,
p=0.0006) in incidence of P. vivax episodes of any density and a
55% reduction (95% CI 34–59, p,0.0001) in incidence of P. vivax
episodes with .500 parasites/ml. There were no significant
associations with all P. falciparum episodes (incidence rate ratio
[IRR]= 1.03, 95% CI 0.73–1.45, p=0.89) (Table 1) or episodes
with P. falciparum .2,500 parasites/ml (IRR=1.03, 95% CI 0.69–
1.55, p=0.86).
SAO and Prevalence and Density of Malaria Infection
In children 3–21 mo, the prevalence and density of P. vivax and
P. falciparum were evaluated in 6,269 blood samples collected at
scheduled 3-monthly study contacts. Of these, 1,435 (22.9%) and
352 (5.6%) were positive for P. vivax and P. falciparum, respectively,
by LDR-FMA and 843 (12.9%) and 197 (3.0%) by LM. Infections
with P. malariae and P. ovale were rare even by LDR-FMA (1.3%
and 0.5%, respectively). There was no significant difference in the
prevalence P. vivax infections in SAO and wild-type children
#12 mo (Table 2). However, in SLC4A1D27 heterozygous
children aged 15–21 mo, significantly fewer P. vivax infections
were detected by both LDR-FMA (adjusted odds ratio [aOR]
0.71, p=0.041) and LM (aOR 0.39, p=0.001). In children of all
ages, P. vivax parasite densities (by LM) were significant lower in
SLC4A1D27 heterozygous children (1,111/ml versus 636/ml,
p=0.011) (Figure 1). By contrast, the prevalence of P. falciparum
was higher in SLC4A1D27 heterozygous children (reaching
statistical significance only for LDR-FMA positive infections)
(Table 1), but parasite densities were comparable (1,642/ml versus
2,104/ml, p=0.59).
Of the 206 children 5–14 y of age enrolled in the treatment-
reinfection cohort 106 (51.5%) were female; 116 (56.9%) were
over 8 y of age. 27 children (13.1%) were heterozygous for
SLC4A1D27. SLC4A1D27 heterozygous children, were similar in
the basic characteristics to wild-type children except that
significantly more of them were attending Mugil Elementary
School (96.3% versus 70.4%, p=0.004) (Table S2). There were no
significant associations between SAO and a+-thalassaemia or
GPYCDex3 genotypes [46]. Genotype frequencies did not differ
with age and sex (Fisher exact test, p.0.4 [8]). All children were
wild-type (FY*A/FY*A) for the Duffy antigen.
Following initial blood-stage malaria therapy, children rapidly
acquired LM-detectable blood-stage infections, with 156/192
(81.2%), 102/206 (49.5%), and 17/206 (8.3%) acquiring one or
more P. falciparum, P. vivax, and P. malariae infections, respectively,
over the 26 wk of observation. Similarly, using LDR-FMA
diagnosis, the proportions of reinfected children rose to 91.6%,
82%, and 29.3%, respectively [30].
While SLC4A1D27 heterozygous and wild-type children had
similar times to reinfection with P. falciparum [8], a significantly
lower proportion of heterozygous children acquired P. vivax and P.
malariae reinfections during the follow-up time period (Figure 2).
Among SLC4A1D27 heterozygotes, 70.3% (19/27) acquired at
least one LDR-FMA-positive P. vivax infection compared to 83.8%
(149/179) of non-SAO children (log rank test, x2 = 9.68, df = 1,
p=0.002) over the period of observation. Similarly, P. vivax
infections were observed in only 37% (10/27) of SLC4A1D27
heterozygotes by microscopy, compared to 54.7% (98/179) of
non-SAO children (log rank test, x2 = 6.5, df = 1, p=0.011). After
correction for all other factors found to be associated with
differences in risk of reinfection [30], SLC4A1D27 heterozygosity
was associated with a significant 52% reduction in time to first
LDR-FMA (adjusted hazard ratio (aHR): 0.48, p=0.003) (Table 3)
and 55% reduction in time to first LM-detectable P. vivax
infections (aHR: 0.45, p=0.014), as determined by Cox regression
analysis. Similarly, SAO was associated with a 71% reduction in
time to first LDR-FMA-detectable (aHR: 0.29, p=0.03) P. malariae
infections. SAO was however not associated with protection
against P. falciparum (Table 3) [8].
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Duffy Expression and PvDBP Binding on SAO Red Cells
A possible mechanism whereby SLC4A1D27 may confer
protection against P. vivax may be through reduced expression
and altered functionality of the Duffy antigen receptor on RBCs.
Accordingly, levels of Duffy expression and ability to bind
recombinant PvDBPII were compared on red cells from a subset
SAO (n=11) and non-SAO (n=12) study children. Erythrocytes
with SLC4A1D27 showed no significant decrease in expression of
the Duffy receptor on the surface (Figure 3, left panel, mean 6
standard error of the mean [SEM] normalized mean fluorescence
index [nMFI] = 36,881, inter-quartile range [IQR] 8,455–47,750,
versus 18,360, IQR 9,555–27,040, p=0.42 for SAO and non-
SAO cells, respectively). The ability of PvDBPII to bind to the
different SAO and non-SAO cells was similar (nMFI = 13,755,
IQR 9,757–23,603, versus 12,069, IQR 6,292–20,740, p=0.36)
(Figure 2, right panel).
Table 1. Associations between SAO and incidence of malaria during follow-up in infants 3–21 mo.
Clinical Malaria Wild Type (n=991) SAO (wt/D27, n=130) IRRa 95% CI p-Value
Events PYAR Incidence Events PYAR Incidence
All episodes 1,309 1,288.6 1.02 122 173.0 0.71 0.68 0.51–0.89 0.0062
All Pf episodes 373 1,359.0 0.27 51 178.3 0.29 1.03 0.73–1.46 0.86
Pf.2,500/ml 242 1,368.7 0.18 33 179.7 0.18 1.04 0.69–1.55 0.86
All Pv episodes 1,018 1,309.8 0.78 80 176.1 0.45 0.57 0.41–0.78 0.0005
Pv.500/ml 800 1,326.2 0.60 50 178.3 0.28 0.45 0.31–0.66 ,0.0001
aIRR-AHRs with analyses adjusted for the following potential confounders: gender, village of residence, average bednet usage, season of recruitment, and IPTi treatment
group.
PYAR, person year at risk.
doi:10.1371/journal.pmed.1001305.t001




PR aORc 95% CI PR aORc 95% CI
P. vivax
All children wt/wt 23.1% — — 13.1% — —
wt/D27 19.7% 0.84 0.66–1.05 9.7% 0.72 0.50–1.04
— — (p= 0.13) — — (p= 0.08)
3–12 mo wt/wt 19.1% — — 9.6% — —
wt/D27 17.8% 0.93 0.69–1.25 10.4% 1.12 0.75–1.68
— — (p= 0.64) — — (p= 0.59)
15–21 mo wt/wt 30.3% — — 18.9% — —
wt/D27 23.1% 0.72 0.51–0.99 8.5% 0.39 0.23–0.67
— — (p= 0.044) — — (p= 0.001)
P. falciparum
All children wt/wt 5.2% — — 2.9% — —
wt/D27 8.4% 1.65 1.17–2.32 4.1% 1.51 0.97–2.36
— — (p= 0.004) — — (p= 0.067)
3–12 mo wt/wt 4.0% — — 2.4% — —
wt/D27 6.7% 1.67 1.07–2.62 3.5% 1.45 0.85–2.48
— — (p= 0.024) — — (p= 0.18)
15–21 mo wt/wt 7.3% — — 3.6% — —
wt/D27 11.4% 1.62 1.00–2.64 5.1% 1.41 0.71–2.81
— — (p= 0.052) — — (p= 0.32)
aInfections diagnosed by post-PCR LDR-FMA.
bInfections diagnosed by expert LM.
cAORs with analyses adjusted for the following variables: IPTi treatment group, insecticide treatment bednet usage, village of residence.
PR, prevalence rate.
doi:10.1371/journal.pmed.1001305.t002
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SAO and Generation of P. vivax-Specific Antibody
Responses
Since we had previously shown that high binding inhibitory
antibodies to PvDBPII (.90% inhibitory activity) correlated with
protection against P. vivax in this population [43], we examined
whether SAO affects a generation of protective anti-DBPII
antibodies. Among SLC4A1D27 heterozygous children 6/27
(22.2%) had high levels of PvDBPII BIAbs (.90% strain-
transcending binding inhibition [43]) compared to 12/179
(6.7%, p=0.008) in non-SAO children. Adjusting for the presence
of PvDBP-specific BIAbs did not significantly alter the strength of
protection of SAO against P. vivax infections detected by either
LDR-FMA (aHR=0.49, 95% CI 0.30–0.81, p=0.008) or LM
(aHR=0.49, 95% CI 0.25–0.95, p=0.036).
In contrast to the above findings, total IgG antibodies as
measured by ELISA to the main variants of PvDBPII (AH, O, and
P) as well as to other P. vivax merozoite surface proteins (PvRBP1,
PvRBP2, and PvMSP119) were not significantly different in SAO
compared with non-SAO children (unpublished data).
Prevalence of SAO among Severe Malaria Cases
Of 318 cases fulfilling the standard WHO definition of severe
malaria, 273 were infected with P. falciparum, 34 with P. vivax, ten
with P. falciparum plus P. vivax, and one with P. malariae. Of these
264 (83.0%) also fulfilled the pre-defined, more stringent criteria
(parasitaemia cut-offs plus of local Madang or Sepik parentage) for
the host genetic study: 236 were infected with P. falciparum
(.1,000/ml), 25 with P. vivax (.500/ml), two with P. falciparum plus
P. vivax, and one with P. falciparum plus P. malariae. SLC4A1D27
genotyping was successfully preformed in cases and healthy
community controls.
28 of 330 (8.5%) health community controls were heterozygous
for SLC4A1D27 compared with eight of 236 (3.4%) in children
with P. falciparum single infections (OR=0.38, 95% CI 0.15–0.87,
p=0.014) and 0/27 (0%) for children with P. vivax or mixed P.
vivax/P. falciparum infection (OR=0, 95% CI 0–1.56, p=0.11,
exact test).
When all cases fulfilling WHO criteria for severe malaria are
considered, two cases of P. vivax infection (case 1: 429 parasites/ml
with prostration and mildly impaired consciousness (Blantyre
coma score = 4); case 2: 98 parasites/ml (mixed with P. falciparum by
PCR), severe anemia (Hb= 1.7 g/dl), and hyperlactemia (lacta-
te = 6.3 mmol/l) were observed in children with SAO genotype.
Among the eight SAO children with P. falciparum mono-
infection, three presented with deep coma (Blantyre coma scores of
2, 1, and 2 respectively) in presence of P. falciparum densities of
4,266, 219, and 309/ml. All three children had clear CSF and
negative CSF and blood cultures. These three cases are consistent
with the accepted clinical definitions for cerebral malaria caused
by P. falciparum [23,29]. A detailed clinical description of each case
is given in Text S1.
Discussion
This study shows that a deletion in an RBC integral membrane
protein SLC4A1D27 causing SAO was associated with a 43%










P. vivax P. falciparum
all 3-12mth 15-21mth all
p = 0.036p = 0.008 p < 0.001
p = 0.65
Figure 1. Parasite density (by LM) in species in SAO (wt/D27, red squares) and non-SAO children (wt/wt, blue rhombi). Significance
levels adjusted for IPTi treatment, insecticide-treated net use, and village of residence.
doi:10.1371/journal.pmed.1001305.g001
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infants followed from age 3 to 21 mo and a 52%–55% reduction
in P. vivax reinfection diagnosed by PCR-LDR-FMA and LM,
respectively, in a cohort of children aged 5–14 y. This is the first in
vivo evidence that SAO may afford partial protection against P.
vivax malaria in two independent, longitudinal cohort studies. In
addition, SAO was associated with a lower P. vivax parasitaemia in
children aged 3–21 mo and a reduced prevalence of P. vivax
infections in children 15–21 mo. Last but not least, no child SAO
genotype was found among 27 cases with severe P. vivax or mixed
P. falciparum/P. vivax malaria. However, SAO was not associated
with protection against P. falciparum infection and uncomplicated
disease. While it was associated with a decreased risk of severe P.
falciparum malaria, at least one severe malaria case with SAO
genotype was admitted with deep coma (Blantyre Coma score = 2),
refuting the earlier assertion that SAO provides complete
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Figure 2. Time-to-first blood-stage infections with different Plasmodium species in SAO (dashed) and non-SAO children (solid).
Kaplan-Meier Curves with log-rank test for difference.
doi:10.1371/journal.pmed.1001305.g002
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SAO is a dominant phenotype with respect to RBC morphol-
ogy. All individuals who are SLC4A1D27 heterozygous have
erythrocytes that are ovalocytic and more rigid than normal [48].
Although it has been suggested that the mutated band 3 protein
retains its normal secondary structure [49], the membrane domain
is modified [49] and the variant protein does not conduct anion
transport normally [50]. While SAO erythrocytes exhibit approx-
imately half of the anion transport activity of normal erythrocytes
[50], this does not contribute to anemia or significantly impair
erythrocyte function [51]. Despite being lethal in its homozygous
state [4], the prevalence of heterozygosity reaches 35% in some
coastal populations in PNG [3], indicating a strong selective
advantage of the heterozygous genotype. Until now protection
against P. falciparum cerebral malaria has been considered the most
likely cause of selection for SAO [5,47]. The strong reduction in
the incidence of P. vivax disease and infections observed in our
study opens up the possibility that protection against P. vivax
malaria could at least have contributed to the heterozygote
advantage of SAO in PNG.
It is now well established that both P. falciparum and P. vivax are
associated with severe disease and death in Melanesian popula-
tions [9,10,29,52]. In our studies in PNG, although P. vivax
infections were less likely to result in severe symptoms, children
admitted with severe P. vivax had the same phenotype as those with
severe P. falciparum infections, while those with mixed P. falciparum/
P. vivax presented with the most severe illness and the greatest
mortality [29]. Absence of any cases of severe vivax malaria with a
parasitaemia .500/ml indicates that SAO could result in a P.
vivax-specific mortality benefit. However, the limited number of
both SAO children and severe P. vivax infections in our case-
control study restricts our ability to assess this association. Larger,
appropriately powered studies are therefore required to confirm
this finding.
The mechanism by which SAO may protect against P. vivax
infection and disease is unknown. The changes to the RBC
membrane and anion transport across the membrane caused by
SAO could impact development of malarial parasites in several
ways. SAO may alter the ability of the parasite to develop within
the erythrocyte. The altered membrane characteristics of SAO
erythrocytes may impair the parasite’s ability to remodel the RBC
Table 3. Associations between SAO and to first Plasmodium




aHRc 95% CI LMb aHRd 95% CI
P. vivax wt/wt 179 — — — —
wt/D27 27 0.48 0.29–0.78 0.45 0.23–0.87
— — (p= 0.003) — (p= 0.014)
P. malariae wt/wt 179 — — — —
wt/D27 27 0.29 0.09–0.91 0.0e —
— — (p= 0.033) — (p= 0.0)e
P. falciparum wt/wt 168 — — — —
wt/D27 25 1.15 0.75–1.76 1.32 0.85–2.04
aInfections diagnosed by post-PCR LDR-FMA.
bInfections diagnosed by expert LM.
cAHRs with analyses adjusted for the following significant confounders: P. vivax,
presence of LM+ Pv infection at baseline; P. falciparum, distance from residence
to local health centre; P. malariae, none.
dAHRs with analyses adjusted for the following significant confounders: P. vivax,
age .9 y; P. falciparum, distance from residence to local school elementary
school+LDR-FMA positive Pf infection at baseline; P. malariae, distance from
residence to local health centre and to local elementary school.
eAs LM-positive P. malariae infection were observed among SAO children,



















Figure 3. Duffy receptor expression on erythrocytes as measured by mAb Fy6 on SAO and non-SAO cells (left panel) and binding of
PvDBPII to its’ receptor on SAO and non-SAO cells (right panel). Each spot represents analysis of 56105 erythrocytes from a single donor.
doi:10.1371/journal.pmed.1001305.g003
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surface [53] and affect deformability of the infected erythrocytes
resulting in impaired transit through capillaries, while the changes
induced by the decrease in anion transport and gas exchange [54]
might inhibit growth of parasites inside the SAO RBC.
Alternatively, SAO may alter the ability of P. vivax to attach to
and/or invade reticulocytes Although SAO reduced parasite
densities even in infants aged #12 mo, this resulted in a reduced
prevalence of infection only in the second year of life. This
indicates that SAO cells may not be inherently resistant to P. vivax
infection, but that children acquire this protective effect only in
concert with increasing acquisition of anti-blood-stage immunity,
either by increasing the acquisition and/or by enhancing the
protective effect of immune response. A similar interaction
between host genetics and age-specific immune status has recently
be shown for the sickle cell trait (HbAS), where in cohort of
Ugandan children the youngest children were best protected
against high density parasitaemia, while only older children were
protected against establishment of parasitaemia [55].
In contrast to normal RBCs where band 3 is mainly found as
dimers, protein expressed from the SLC4A1D27 allele may induce
conformational changes in the normal band 3 protein resulting in
the predominance of band 3 hetero-tetramers, higher order
hetero-oligomers, and aggregates in SAO RBCs [56]. How this
influences the distribution of other RBC membrane proteins is not
known. The predominance of higher order band 3 aggregates in
SAO RBCs could, however, have a significant impact on the
interaction between parasite ligands and RBC proteins in general,
and specifically on the invasion of P. vivax via the Duffy antigen
that is thought to be part of a 4.1R-based macromolecular
complex that contains band 3 as a dimer [42].
In our studies that further explored the relationship between
SAO and the Duffy antigen, fluorescence activated cell sorting
(FACS)-based analyses revealed that SAO and non-SAO red cells
expressed similar amounts of surface-level Duffy antigen and that
PvDBPII bound to SAO and non-SAO cells equally well.
Interestingly, we found that while antibody levels to PvDBPII
measured by ELISA did not differ, SAO children were 3.3 times
more likely than non-SAO children to have high levels of
PvDBPII-specific BIAbs. This preferential production of function-
al BIAbs could occur because critical binding regions of PvDBP
might be exposed for a longer period of time during less efficient
invasion of SAO cells, making the protein more accessible to the
host immune response that generate broadly binding inhibitory
antibodies. Adjusting for blocking antibodies did not, however,
change the magnitude of the protection provided by SAO against
reinfection with P. vivax. Thus, while SAO increases the likelihood
that high activity Duffy blocking antibodies are acquired, the
protection attributed to SAO is distinct from that provided by
Duffy blocking antibodies. Further study of SAO-based protection
against P. vivax illness, in particular in small children who suffer the
highest morbidity burdens of P. vivax morbidity [9], is required to
determine how this mutation imparts its selective advantage.
Irrespective of the mechanism by which this mutation evolved,
our observations highlight the potential contribution of P. vivax
malaria in shaping the unique RBC polymorphisms found in
Asian and Pacific populations. Future studies on host genetic
adaptation in the Asia Pacific region should thus not exclusively
focus on P. falciparum but need to include other human malaria
species.
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Editors’ Summary
Background. Hereditary blood disorders are widely prev-
alent in different regions around the world and the type of
disorder depends on the population gene pool. For example,
sickle cell disease is indigenous to sub-Saharan Africa, and
Southeast Asian ovalocytosis (SAO), as the name suggests, to
Southeast Asia and the South West Pacific, particularly
Malaysia and Papua New Guinea. In SAO, the red blood cells
(erythrocytes) are a different shape (elliptical) from the usual
biconcave disc shape due to a genetic defect (caused by
band 3 deletion SLC4A1D27) in the red blood cell membrane.
This defect is carried by up to 35% of people living on the
coasts of Papua New Guinea, and as these areas match high
malaria endemic areas, it is thought that carrying this defect
is associated with improved survival against malaria in these
populations—some studies have suggested that SAO is
associated with complete protection against cerebral malaria
but not other forms of malaria caused by the same type of
parasite—P. falciparum.
Why Was This Study Done? Although P. falciparum gains
most attention by the international health community as it
causes the most severe types of malaria, recent epidemio-
logical studies suggest that malaria caused by P. vivax can
also cause severe illness in some areas of the world where it
is highly prevalent. Furthermore, detailed genetic and
laboratory studies have suggested that the genetic defect
associated with SAO may actually protect against infection
from P. vivax malaria. So in this study, the researchers
examined the relationship of the SAO genetic defect and P.
vivax malaria by doing genetic tests on children in Papua
New Guinea—an area in which both conditions are widely
prevalent.
What Did the Researchers Do and Find? The researchers
performed genetic tests for the SAO defect in 1,975 children
in the Madang area of Papua New Guinea who were
participating in three separate malaria studies that were
conducted over different time periods: (i) a cohort of 1,121
infants aged 3–21 months participating in a clinical drug trial
of intermittent preventative treatment of malaria; (ii) a case-
control study of 318 children with severe malaria aged 10
years and under; and (iii) a cohort of 206 children aged 5–14
years who took part in a prospective study to evaluate the
time of reinfection with all forms of malaria. Given the
different nature of these studies, for example, the effect of
intermittent treatment for which the researchers had to
make statistical adjustments, the researchers analysed the
presence of the SAO genetic defect and the incidence of all
forms of malaria separately to calculate the association with
SAO and malaria in the participants in each study.
The researchers found that the SAO genetic defect present in
130 infants (11.6%) in the first study and 27 (13.1%) children
in the third study. In the case-control study, the researchers
found that 28 of the 330 controls (8.5%) had the SAO genetic
defect compared to eight of 236 (3.4%) in children with P.
falciparum single infections. Overall, the researchers found
that the SAO genetic defect was associated with a 43%
reduction in risk of clinical P. vivax episodes in the infants in
the first study and a 52%–55% reduction in P. vivax
reinfection in children in the third study. Furthermore, from
the limited data from the second study, the researchers
found that none of the children with P. vivax or mixed P.
falciparum/P. vivax malaria had the SAO defect, which may
indicate a protective effect.
What Do These Findings Mean? These findings suggest
that the SAO genetic defect (SLC4A1D27) may have a
protective effect against malaria caused by P. vivax in infants
and children of different ages in Papua New Guinea.
However, although it seems likely that SAO may alter the
ability of the malarial parasite to develop within the red
blood cell, this study sheds no further light on the way in
which the SAO genetic defect may protect against P. vivax
infection and disease and so further studies are needed to
investigate possible mechanisms. Importantly, these findings
suggest that future studies investigating genetic adaptation
of diverse populations around the world, particularly in the
Asian Pacific region, should include all forms of human
malaria, such as P. vivax, and not exclusively focus on P.
falciparum.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001305.
N Wikipedia has information on Southeast Asian Ovalocytosis
(note that Wikipedia is a free online encyclopedia that
anyone can edit; available in several languages)
N WHO provides information on malaria
N The US Centers for Disease Control and Prevention provide
information on malaria (in English and Spanish)
N MedlinePlus provides links to additional information on
malaria and on ovalocytosis
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